SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Cytrx Corp – ‘10-K’ for 12/31/13

On:  Tuesday, 3/4/14, at 6:18pm ET   ·   As of:  3/5/14   ·   For:  12/31/13   ·   Accession #:  799698-14-4   ·   File #:  0-15327

Previous ‘10-K’:  ‘10-K’ on 3/11/13 for 12/31/12   ·   Next:  ‘10-K’ on 3/10/15 for 12/31/14   ·   Latest:  ‘10-K’ on 3/27/24 for 12/31/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/05/14  Cytrx Corp                        10-K       12/31/13   77:9.7M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Form 10-K for Fiscal Year Ending 12/31/2013         HTML   1.30M 
 2: EX-4.8      Instrument Defining the Rights of Security Holders  HTML     46K 
 3: EX-10.22    Material Contract                                   HTML     68K 
 4: EX-10.23    Material Contract                                   HTML     53K 
 5: EX-10.24    Material Contract                                   HTML     53K 
 6: EX-10.25    Material Contract                                   HTML     52K 
 7: EX-10.29    Material Contract                                   HTML     24K 
 8: EX-10.30    Material Contract                                   HTML     24K 
 9: EX-10.31    Material Contract                                   HTML     24K 
10: EX-10.32    Material Contract                                   HTML     26K 
11: EX-23.1     Consent of Experts or Counsel                       HTML     22K 
12: EX-31.1     Certification -- §302 - SOA'02                      HTML     26K 
13: EX-31.2     Certification -- §302 - SOA'02                      HTML     26K 
14: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
15: EX-32.2     Certification -- §906 - SOA'02                      HTML     22K 
54: R1          Document and Entity Information                     HTML     49K 
44: R2          Consolidated Balance Sheets                         HTML     95K 
52: R3          Consolidated Balance Sheets (Parenthetical)         HTML     48K 
56: R4          Consolidated Statements of Operations               HTML     70K 
72: R5          Consolidated Statements of Stockholders' Equity     HTML     71K 
46: R6          Consolidated Statements of Cash Flows               HTML    116K 
51: R7          Nature of Business                                  HTML     28K 
41: R8          Summary of Significant Accounting Policies          HTML     71K 
33: R9          Receivables                                         HTML     26K 
73: R10         Prepaid and Other Assets                            HTML     23K 
58: R11         Short-term Investments                              HTML     27K 
57: R12         Equipment and Furnishings                           HTML     31K 
62: R13         Accrued Expenses and Other Current Liabilities      HTML     31K 
63: R14         Warrant Liabilities                                 HTML     36K 
61: R15         Commitments and Contingencies                       HTML     51K 
64: R16         Equity Transactions                                 HTML     33K 
53: R17         Investments in ADVENTRX Pharmaceuticals             HTML     26K 
55: R18         Stock Options and Warrants                          HTML    221K 
60: R19         Sale of Assets                                      HTML     23K 
77: R20         Stockholder Protection Rights Plan                  HTML     25K 
67: R21         Income Taxes                                        HTML     58K 
48: R22         Quarterly Financial Data (Unaudited)                HTML     48K 
59: R23         Subsequent Events                                   HTML     59K 
50: R24         Schedule Ii - Valuation and Qualifying Accounts     HTML     40K 
27: R25         Summary of Significant Accounting Policies          HTML    124K 
                (Policies)                                                       
68: R26         Summary of Significant Accounting Policies          HTML     47K 
                (Tables)                                                         
74: R27         Equipment and Furnishings (Tables)                  HTML     29K 
37: R28         Accrued Expenses and Other Current Liabilities      HTML     30K 
                (Tables)                                                         
36: R29         Warrant Liabilities (Tables)                        HTML     34K 
39: R30         Commitments and Contingencies (Tables)              HTML     45K 
40: R31         Stock Options and Warrants (Tables)                 HTML    218K 
42: R32         Income Taxes (Tables)                               HTML     53K 
26: R33         Quarterly Financial Data (Unaudited) (Tables)       HTML     46K 
65: R34         Subsequent Events (Tables)                          HTML     58K 
47: R35         Nature of Business (Details)                        HTML     40K 
49: R36         Summary of Significant Accounting Policies          HTML     67K 
                (Details)                                                        
30: R37         Receivables (Details)                               HTML     23K 
76: R38         Prepaid and Other Assets (Details)                  HTML     23K 
22: R39         Short-term Investments (Details)                    HTML     26K 
43: R40         Equipment and Furnishings (Details)                 HTML     34K 
71: R41         Accrued Expenses and Other Current Liabilities      HTML     35K 
                (Details)                                                        
29: R42         Warrant Liabilities (Details)                       HTML     41K 
35: R43         Commitments and Contingencies (Details)             HTML     83K 
38: R44         Equity Transactions (Details)                       HTML     49K 
45: R45         Investments in ADVENTRX Pharmaceuticals (Details)   HTML     32K 
25: R46         Stock Options and Warrants (Details)                HTML    304K 
32: R47         Sale of Assets (Details)                            HTML     24K 
23: R48         Stockholder Protection Rights Plan (Details)        HTML     33K 
70: R49         Income Taxes (Details)                              HTML     96K 
28: R50         Quarterly Financial Data (Unaudited) (Details)      HTML     37K 
66: R51         Subsequent Events (Details)                         HTML     87K 
31: R52         Schedule Ii - Valuation and Qualifying Accounts     HTML     32K 
                (Details)                                                        
75: XML         IDEA XML File -- Filing Summary                      XML    100K 
24: EXCEL       IDEA Workbook of Financial Reports                  XLSX    171K 
34: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.26M 
16: EX-101.INS  XBRL Instance -- cytr-20131231                       XML   1.91M 
18: EX-101.CAL  XBRL Calculations -- cytr-20131231_cal               XML    190K 
19: EX-101.DEF  XBRL Definitions -- cytr-20131231_def                XML    469K 
20: EX-101.LAB  XBRL Labels -- cytr-20131231_lab                     XML   1.57M 
21: EX-101.PRE  XBRL Presentations -- cytr-20131231_pre              XML    873K 
17: EX-101.SCH  XBRL Schema -- cytr-20131231                         XSD    162K 
69: ZIP         XBRL Zipped Folder -- 0000799698-14-000004-xbrl      Zip    166K 




        
Filing Submission 0000799698-14-000004 – SGML Text

Original SGML Text submitted by:  LadRx Corp. [ formerly Cytrx Corp. ]

To view the SGML, please refresh
Refresh emoji
this page.


Top

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 6:35:59.1pm ET